Brasília – The Brazilian pharmaceutical industry expects to grow up to 11.5% in revenues in 2025, driven by population ageing, public health programs such as Farmácia Popular, and the continued expansion of generics, according to Sindusfarma president Nelson Mussolini. Volume sales are projected to rise between 4% and 5%.

Despite the optimism, sector leaders warn that challenges persist — including weak enforcement in the sale of prescription medicines, the rapid advance of online channels, and Brazil’s high taxation on pharmaceuticals, estimated at 11%–12%, one of the highest globally.

Mussolini also called for adjustments in the CMED price-control model, arguing for differentiated treatment for incremental innovations and faster implementation of the new clinical-trials framework to strengthen Brazil’s competitiveness in research, where it currently ranks 22nd worldwide.

Source: Panorama Farmacêutico

Want to explore this and other key issues in Brazil’s health system?
Contact us at pharmabrnews@gmail.com